Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

FDA Expands Indications for Regorafenib

New indication concerns the treatment of patients with hepatocellular carcinoma who have been previously treated with sorafenib
28 Apr 2017
Gastrointestinal cancers;  Anticancer agents & Biologic therapy

On 27 April, 2017 the US Food and Drug Administration (FDA) expanded the indications of regorafenib (STIVARGA, Bayer HealthCare Pharmaceuticals Inc.) to include the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.

Approval was based on an international, multicentre, randomised, double-blind, placebo-controlled trial of 573 patients with Child-Pugh A and Barcelona Clinic Liver Cancer Stage B or C HCC with documented disease progression following sorafenib.

Patients were randomly allocated to receive regorafenib 160 mg orally once daily plus best supportive care (BSC) or matching placebo plus BSC for the first 21 days of each 28-day cycle. Treatment continued until disease progression or unacceptable toxicity.

The trial demonstrated a significant improvement in overall survival (HR=0.63, 95% CI: 0.50, 0.79, p<0.0001) with an estimated median overall survival for patients in the regorafenib arm of 10.6 months and 7.8 months for patients in the placebo arm.

A statistically significant improvement was also demonstrated for progression-free survival (PFS) based on modified RECIST for HCC (HR=0.46, 95% CI: 0.37, 0.56, p<0.0001), with an estimated median PFS of 3.1 and 1.5 months in the regorafenib and placebo arms, respectively.

The overall response rate, based on modified RECIST, was 11% in the regorafenib arm and 4% in the placebo arm.

The safety of regorafenib was evaluated in 1142 patients enrolled in randomised, placebo-controlled trials. The most common adverse reactions observed in 20% or more of patients taking regorafenib were pain, hand-foot skin reaction (HFSR), asthenia/fatigue, diarrhoea, decreased appetite, hypertension, infection, dysphonia, elevated bilirubin, fever, mucositis, weight loss, rash, and nausea.

The recommended regorafenib dose is 160 mg (four 40 mg tablets) taken orally once daily after a low-fat meal for the first 21 days of each 28-day cycle.

Full prescribing information is available here.

FDA granted this application priority review and Orphan Drug Designation.

Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System.

Last update: 28 Apr 2017

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.